Grassi Giacomo, Moradei Corinna, Cecchelli Chiara
Brain Center Firenze, 50144 Florence, Italy.
Life (Basel). 2023 Jul 1;13(7):1494. doi: 10.3390/life13071494.
Although in 2017 a repetitive transcranial magnetic stimulation (rTMS) protocol received Food and Drug Administration approval for the first time for the treatment of obsessive-compulsive disorder (OCD), which neural target and which protocol should be used for OCD are still debated. The aim of the present study was to perform a systematic review and meta-analysis of the available open and sham-controlled trials.
The primary analysis included a pairwise meta-analysis (over 31 trials), and then subgroup analyses were performed for each targeted brain area. Meta-regression analyses explored the possible moderators of effect size.
The pairwise meta-analysis showed a significant reduction in OCD symptoms following active rTMS (g = -0.45 [95%CI: -0.62, -0.29]) with moderate heterogeneity (I = 34.9%). Subgroup analyses showed a significant effect of rTMS over the bilateral pre-SMA (supplementary motor area), the DLPFC (dorsolateral prefrontal cortex), the ACC/mPFC (anterior cingulate cortex and medial prefrontal cortex), and the OFC (orbitofrontal cortex). No moderators of the effect size emerged.
TMS of several brain targets represents a safe and effective treatment option for OCD patients. Further studies are needed to help clinicians to individualize TMS protocols and targets for each patient.
尽管在2017年,一种重复经颅磁刺激(rTMS)方案首次获得美国食品药品监督管理局批准用于治疗强迫症(OCD),但对于OCD应使用哪个神经靶点以及哪种方案仍存在争议。本研究的目的是对现有的开放试验和假对照试验进行系统评价和荟萃分析。
主要分析包括成对荟萃分析(超过31项试验),然后对每个靶向脑区进行亚组分析。荟萃回归分析探讨了效应大小的可能调节因素。
成对荟萃分析显示,主动rTMS治疗后OCD症状显著减轻(g = -0.45 [95%CI:-0.62,-0.29]),异质性中等(I = 34.9%)。亚组分析显示,rTMS对双侧前辅助运动区(pre-SMA)、背外侧前额叶皮质(DLPFC)、前扣带回皮质和内侧前额叶皮质(ACC/mPFC)以及眶额皮质(OFC)有显著影响。未发现效应大小的调节因素。
对几个脑靶点进行TMS治疗是OCD患者一种安全有效的治疗选择。需要进一步研究以帮助临床医生为每位患者个体化制定TMS方案和靶点。